Study S000990

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04057261
Acronym: Lirabolic
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2020-11
Primary completion: 2022-08
Lead sponsor: RWTH Aachen University
Conditions: Type 2 Diabetes; Cardiovascular Diseases
Interventions: DRUG:Liraglutide Pen Injector [Victoza]; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months [3 month]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.